Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Willemijn S M E Theelen, Dawei Chen, Vivek Verma...
https://pubmed.ncbi.nlm.nih.gov/33096027/Actively Recruiting
Led by Shanghai Pulmonary Hospital, Shanghai, China · Updated on 2026-08-10
78
Participants Needed
5
Research Sites
N/A
Total Duration
This trial focuses on patients aged 70 years or older with resectable stage IIA-IIIB non-small cell lung cancer NSCLC who do not have certain genetic alterations EGFR, ALK, ROS1. Researchers are evaluating a combination of oral paclitaxel solution, immune checkpoint inhibitors, and stereotactic body radiotherapy SBRT as a neoadjuvant treatment before surgery. The study aims to assess safety, tolerability, and preliminary effectiveness of this approach in older adults who may have higher risks from standard therapies. During Phase I, participants receive escalating doses of oral paclitaxel solution 80, 120, 160 mgm on Days 1 and 8 of each cycle, divided into morning and evening doses, combined with an anti-PD-1 or anti-PD-L1 monoclonal antibody and SBRT delivered as 8 Gy per fraction for 3 fractions. Phase II enrolls more participants at the recommended dose to further assess antitumor activity. Participants suitable for surgery after neoadjuvant therapy may undergo radical lung cancer surgery, while others receive definitive radiotherapy. Participants will undergo tumor response assessments through pathology and imaging, surgical evaluation if operable, and long-term follow-up for event-free and overall survival. Researchers will monitor treatment-related adverse events, pathologic complete response, and biomarker changes including immune cells, circulating tumor DNA, and PD-L1 expression. The study duration extends through treatment and follow-up until 2028, with careful safety and efficacy evaluations at multiple timepoints.
CONDITIONS
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
X
Xiaoling Xu, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shanghai Pulmonary Hospital, Shanghai, China
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Several treatment cycles with dose escalation
Participants receive escalating doses of oral paclitaxel solution on Days 1 and 8 of each cycle, combined with an anti-PD-1 or anti-PD-L1 antibody and stereotactic body radiotherapy (SBRT) delivered in 3 fractions.
Duration - Up to several months depending on treatment and evaluation
Participants receive oral paclitaxel at the recommended dose with immunotherapy and SBRT. Those suitable for surgery after treatment undergo tumor assessment and radical lung cancer surgery.
Duration - Ongoing follow-up after treatment
Participants unsuitable for surgery receive oral paclitaxel with immunotherapy and definitive radiotherapy. They undergo imaging assessments and long-term survival follow-up.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Willemijn S M E Theelen, Dawei Chen, Vivek Verma...
https://pubmed.ncbi.nlm.nih.gov/33096027/Mark Sorin, Connor Prosty, Louis Ghaleb...
https://pubmed.ncbi.nlm.nih.gov/38512301/Jiacong Liu, Xuhua Huang, Yuhong Yang...
https://pubmed.ncbi.nlm.nih.gov/39614293/Ze-Rui Zhao, Shi-Liang Liu, Ting Zhou...
https://pubmed.ncbi.nlm.nih.gov/39305910/Saurav Verma, Daniel Breadner, Abhenil Mittal...
https://pubmed.ncbi.nlm.nih.gov/38610980/Joe Y Chang, Steven H Lin, Wenli Dong...
https://pubmed.ncbi.nlm.nih.gov/37478883/Salma K Jabbour, Ki Hyeong Lee, Nikolaj Frost...
https://pubmed.ncbi.nlm.nih.gov/34086039/Shanghai Pulmonary Hospital, Shanghai, China
Lead Sponsor